嘉晨西海生物技術(shù)有限公司創(chuàng)始人王子豪博士畢業(yè)于美國約翰霍普金斯大學(xué)，畢業(yè)后曾就職于多個國際大型制藥企業(yè)長達 11 年之久，在職期間直接參與過四價流感、艾滋病、狂犬病、呼吸道合胞病毒、人巨細胞病毒等疫苗的 CMC 開發(fā)。
王子豪博士作為最早參與自復(fù)制 mRNA 工藝設(shè)計優(yōu)化和產(chǎn)業(yè)化開發(fā)的人員之一，專注于 mRNA 技術(shù)平臺的工藝開發(fā)8年，并且直接參與了 mRNA 技術(shù)平臺在多個病毒傳染病領(lǐng)域的有效性及安全性驗證和臨床開發(fā)等。
Dr. Zihao Wang is the Chief Executive Officer at Immorna and Co-founder of the Immorna family of companies. Dr. Wang is a seasoned entrepreneur and established biopharmaceutical veteran. He has over 14 years of biotech R&D and leadership experience. He is one of the pioneers in self-replicating mRNA (srRNA) CMC development and is the mastermind behind the development of the mRNA platform technologies at Immorna, which include an improved next generation srRNA, conventional mRNA, and circular RNA. Dr. Wang pioneers the application of srRNA-LNP against oncology indications.
Prior to founding the Immorna family of companies, Dr. Wang held various R&D roles at GSK Vaccines, Novartis Vaccines and Diagnostics, Grifols SA, etc. During his tenure at Novartis and GSK, he spent more than 7 years working directly on srRNA CMC development and the application of srRNA technology against various viral infectious diseases.
Dr. Wang is the lead author on more than 20 publications with more than 2000 citations. He is also the inventor on multiple patents related to mRNA design, RNA delivery, and their applications in various disease areas. Dr. Wang received his B.S. in Biochemistry from Fudan University in Shanghai, and his Ph.D. in Biological Chemistry from The Johns Hopkins University.